Among the new drugs in development, one of the most closely watched comes from Amylyx Pharmaceuticals, a Cambridge, Massachusetts-based company. Last year, results from a small study showed patients treated with Amylyx's drug, known as AMX0035, appeared to do modestly better at performing essential functions like speaking, walking and writing compared to those who got a placebo. The study also found patients had slower functional declines and lived longer after receiving AMX0035.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,